Sanofi’s fiscal year 2024 results were in line with expectations, with a noteworthy performance in their Vaccines division, particularly driven by Beyfortus. This offset a slight ...

Innovation was a key driver of our growth as launches already contributed 11% of sales, with Beyfortus becoming a blockbuster in its first full year of sales. “As we enter 2025, we expect continued, ...

Lantus sales rose 63.4% to €439.0 million. SNY & AZN’s Beyfortus Drives Vaccine Sales Total vaccine sales increased 10.8% to €2.2 billion, driven by Beyfortus sales in Europe. Sales of flu ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden child could be emerging in the form of Beyfortus. During its first ...

The company's research-and-development spending increased 24% on-year in the last quarter in an attempt to bring further blockbusters such as its respiratory syncytial virus vaccine Beyfortus to ...

Innovation was a key driver of our growth as launches already contributed 11 percent of sales, with Beyfortus becoming a blockbuster in its first full year of sales. We exceeded our business EPS ...

Pharma launches up 56.5%, reaching sales of €0.8 billion, 8% of total sales, led by ALTUVIIIO Dupixent sales up 16.0% to €3.5 billion Vaccines sales up 10.8% to €2.2 billion, driven by Beyfortus sales ...

1 Changes in net sales are at constant exchange rates (CER) unless stated otherwise (definition in Appendix 9). 2 To facilitate an understanding of operational performance, Sanofi comments on the ...

driven by Beyfortus sales in Europe Business EPS of €1.31, -11.0% at CER and -14.9% reported; IFRS EPS of €0.54 In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER 5 ...

The beyfortus market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX ...

In this new segment from pharmaphorum, we collect the most significant hirings, firings, and recruitment stories from across the industry. This month, we highlight new appointments from Lumeris ...